Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 513

1.

Molecular Characterization of Renal Cell Carcinoma: A Potential three microRNA Prognostic Signature.

Lokeshwar SD, Talukder A, Yates TJ, Hennig MJP, Garcia-Roig M, Lahorewala SS, Mullani NN, Klaassen Z, Kava BR, Manoharan M, Soloway MS, Lokeshwar V.

Cancer Epidemiol Biomarkers Prev. 2018 Feb 12. pii: cebp.0700.2017. doi: 10.1158/1055-9965.EPI-17-0700. [Epub ahead of print]

PMID:
29440068
2.

Challenging Cases in Urothelial Cancer.

Soloway MS.

Bladder Cancer. 2018 Jan 20;4(1):129-130. doi: 10.3233/BLC-179026. No abstract available.

3.

Challenging Cases in Urothelial Cancer.

Soloway MS.

Bladder Cancer. 2017 Oct 27;3(4):311-312. doi: 10.3233/BLC-179025. No abstract available.

4.

Editorial Comment.

Soloway MS.

J Urol. 2018 Feb;199(2):406. doi: 10.1016/j.juro.2017.08.126. Epub 2017 Oct 31. No abstract available.

PMID:
29097189
5.

Active Surveillance or Office Fulguration for Low Grade Ta Bladder Tumors: A Win-Win for Patients and Urologists.

Soloway MS.

J Urol. 2017 Oct 5. pii: S0022-5347(17)77672-0. doi: 10.1016/j.juro.2017.09.123. [Epub ahead of print] No abstract available.

PMID:
28987859
6.

Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets.

Morera DS, Hennig MS, Talukder A, Lokeshwar SD, Wang J, Garcia-Roig M, Ortiz N, Yates TJ, Lopez LE, Kallifatidis G, Kramer MW, Jordan AR, Merseburger AS, Manoharan M, Soloway MS, Terris MK, Lokeshwar VB.

Br J Cancer. 2017 Nov 7;117(10):1507-1517. doi: 10.1038/bjc.2017.318. Epub 2017 Oct 3.

PMID:
28972965
7.

Challenging Cases in Urothelial Cancer.

Soloway MS.

Bladder Cancer. 2017 Jul 27;3(3):225-226. doi: 10.3233/BLC-179019. No abstract available.

8.

BCG for high grade NMIBC - Lessons learned over 40 years.

Soloway MS.

Can J Urol. 2017 Jun;24(3):8794. No abstract available.

9.

Challenging Cases in Urothelial Cancer.

Soloway MS.

Bladder Cancer. 2017 Apr 27;3(2):139-140. doi: 10.3233/BLC-179015. No abstract available.

10.
11.

Challenging Cases in Urothelial Cancer.

Soloway MS.

Bladder Cancer. 2017 Jan 27;3(1):73. doi: 10.3233/BLC-169013. No abstract available.

12.

Challenging Cases in Urothelial Cancer.

Soloway MS.

Bladder Cancer. 2016 Oct 27;2(4):465-466. doi: 10.3233/BLC-169012. No abstract available.

13.

Nocturia.

Soloway MS, Weiss JP, Wein AJ.

Curr Urol Rep. 2016 Oct;17(10):77. doi: 10.1007/s11934-016-0632-0.

PMID:
27595997
14.

Challenging Case: Stones.

Soloway MS, Ziemba JB, Matlaga BR, Monga M.

Curr Urol Rep. 2016 Oct;17(10):75. doi: 10.1007/s11934-016-0631-1.

PMID:
27566646
15.

Ct2 Bladder Cancer.

Soloway MS.

Curr Urol Rep. 2016 Sep;17(9):66. doi: 10.1007/s11934-016-0624-0.

PMID:
27457483
16.

Prostate capsule sparing radical cystectomy - a safe procedure for few.

Smith ZL, Soloway MS.

Cent European J Urol. 2016;69(1):32-3. doi: 10.5173/ceju.2016.e109. Epub 2016 Feb 26. No abstract available.

17.

Bladder cancer: Active surveillance for low-grade Ta bladder tumours.

Soloway MS.

Nat Rev Urol. 2016 Jun;13(6):303-4. doi: 10.1038/nrurol.2016.35. Epub 2016 Feb 16. No abstract available.

PMID:
26878804
18.

Expectant Management of Low-Risk Bladder Cancer.

Smith ZL, Soloway MS.

Curr Urol Rep. 2015 Dec;16(12):82. doi: 10.1007/s11934-015-0555-1. Review.

PMID:
26486930
19.

Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes.

Rink M, Crivelli JJ, Shariat SF, Chun FK, Messing EM, Soloway MS.

Eur Urol Focus. 2015 Aug;1(1):17-27. doi: 10.1016/j.euf.2014.11.001. Epub 2015 May 19. Review.

PMID:
28723350
20.

Prognostic significance of cystoscopy findings following neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Mansour AM, Soloway MS, Eldefrawy A, Singal R, Joshi S, Manoharan M.

Can J Urol. 2015 Apr;22(2):7690-7.

PMID:
25891331
21.

Impact of 2004 ISUP/WHO classification on bladder cancer grading.

Lokeshwar SD, Ruiz-Cordero R, Hupe MC, Jorda M, Soloway MS.

World J Urol. 2015 Dec;33(12):1929-36. doi: 10.1007/s00345-015-1548-x. Epub 2015 Apr 2.

PMID:
25833661
22.

Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer.

Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, Lin O, McKenney JK, Montironi R, Paner GP, Al-Ahmadie HA, Algaba F, Ali S, Alvarado-Cabrero I, Bubendorf L, Cheng L, Cheville JC, Kristiansen G, Cote RJ, Delahunt B, Eble JN, Genega EM, Gulmann C, Hartmann A, Langner C, Lopez-Beltran A, Magi-Galluzzi C, Merce J, Netto GJ, Oliva E, Rao P, Ro JY, Srigley JR, Tickoo SK, Tsuzuki T, Umar SA, Van der Kwast T, Young RH, Soloway MS.

Mod Pathol. 2015 May;28(5):612-30. doi: 10.1038/modpathol.2014.158. Epub 2014 Nov 21. Review.

23.

Pathology examination cannot be done without a urologist's help.

Soloway MS.

Cent European J Urol. 2014;67(3):233. doi: 10.5173/ceju.2014.03.art3. No abstract available.

24.

Approaching the optimal transurethral resection of a bladder tumor.

Jurewicz M, Soloway MS.

Turk J Urol. 2014 Jun;40(2):73-7. doi: 10.5152/tud.2014.94715. Review.

25.

Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper.

Culkin DJ, Exaire EJ, Green D, Soloway MS, Gross AJ, Desai MR, White JR, Lightner DJ.

J Urol. 2014 Oct;192(4):1026-34. doi: 10.1016/j.juro.2014.04.103. Epub 2014 May 21. Review.

PMID:
24859439
26.

Editorial comment.

Tiu A, Soloway MS.

Cent European J Urol. 2013;66(1):82. doi: 10.5173/ceju.2013.01.art26. No abstract available.

27.

Bladder cancer - How to improve?

Soloway MS.

Cent European J Urol. 2013;66(1):7. doi: 10.5173/ceju.2013.01.art1. No abstract available.

28.

Differential expression of SDF-1 isoforms in bladder cancer.

Gosalbez M, Hupe MC, Lokeshwar SD, Yates TJ, Shields J, Veerapen MK, Merseburger AS, Rosser CJ, Soloway MS, Lokeshwar VB.

J Urol. 2014 Jun;191(6):1899-1905. doi: 10.1016/j.juro.2013.11.053. Epub 2013 Nov 26.

29.

Re: overdiagnosis and overtreatment in cancer: an opportunity for improvement.

Soloway MS.

Eur Urol. 2014 Jan;65(1):249-50. doi: 10.1016/j.eururo.2013.10.023. No abstract available.

PMID:
24289854
30.

Giant neobladder stone.

Tiu A, Soloway MS.

ANZ J Surg. 2014 May;84(5):390-1. doi: 10.1111/ans.12276. Epub 2013 Oct 29. No abstract available.

PMID:
24168146
31.

Prostate cancer and the increasing role of active surveillance.

Alonzo DG, Mure AL, Soloway MS.

Postgrad Med. 2013 Sep;125(5):109-16. doi: 10.3810/pgm.2013.09.2705.

PMID:
24113669
32.

Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.

Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, Jarrard DF.

Cancer. 2013 Nov 15;119(22):3992-4002. doi: 10.1002/cncr.28303. Epub 2013 Sep 4.

33.

Comparative validation of nomograms predicting clinically insignificant prostate cancer.

Iremashvili V, Soloway MS, Pelaez L, Rosenberg DL, Manoharan M.

Urology. 2013 Jun;81(6):1202-8. doi: 10.1016/j.urology.2013.01.062. Epub 2013 Apr 3.

PMID:
23561706
34.

Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression.

Iremashvili V, Burdick-Will J, Soloway MS.

BJU Int. 2013 Jul;112(1):39-44. doi: 10.1111/bju.12112. Epub 2013 Apr 2.

35.

Active surveillance for low-risk bladder cancer.

Tiu A, Jenkins LC, Soloway MS.

Urol Oncol. 2014 Jan;32(1):33.e7-10. doi: 10.1016/j.urolonc.2012.12.003. Epub 2013 Mar 19. Review.

PMID:
23518309
36.

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion.

Eldefrawy A, Soloway MS, Katkoori D, Singal R, Pan D, Manoharan M.

Indian J Urol. 2012 Oct;28(4):424-6. doi: 10.4103/0970-1591.105756.

37.
38.

Screening for bladder cancer: rationale, limitations, whom to target, and perspectives.

Larré S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB.

Eur Urol. 2013 Jun;63(6):1049-58. doi: 10.1016/j.eururo.2012.12.062. Epub 2013 Jan 8. Review.

PMID:
23313034
39.

Inflammatory changes and the prostate.

Soloway MS.

Cent European J Urol. 2013;66(3):263-4. doi: 10.5173/ceju.2013.03.art3. No abstract available.

40.

Prognostic implications of partial sampling of radical prostatectomy specimens: comparison of 3 methods.

Iremashvili V, Lokeshwar SD, Jorda M, Pelaez L, Soloway MS.

J Urol. 2013 Jul;190(1):84-90. doi: 10.1016/j.juro.2012.12.021. Epub 2012 Dec 14.

PMID:
23246479
41.

A multi-institutional evaluation of active surveillance for low risk prostate cancer.

Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau B.

J Urol. 2013 Jan;189(1 Suppl):S19-25; discussion S25. doi: 10.1016/j.juro.2012.11.023.

PMID:
23234624
42.

Diffuse large B cell lymphoma of the spermatic cord: a case report and literature review.

Joshi S, Mansour AM, Eldefrawy A, Soloway MS.

Can J Urol. 2012 Dec;19(6):6581-3. Review.

PMID:
23228297
43.

Bladder cancer: Lack of progress in bladder cancer--what are the obstacles?

Soloway MS.

Nat Rev Urol. 2013 Jan;10(1):5-6. doi: 10.1038/nrurol.2012.219. Epub 2012 Nov 20. No abstract available.

PMID:
23165404
44.

Prostate cancers of different zonal origin: clinicopathological characteristics and biochemical outcome after radical prostatectomy.

Iremashvili V, Pelaez L, Jordá M, Manoharan M, Rosenberg DL, Soloway MS.

Urology. 2012 Nov;80(5):1063-9. doi: 10.1016/j.urology.2012.08.012.

PMID:
23107397
45.

Partial sampling of radical prostatectomy specimens: detection of positive margins and extraprostatic extension.

Iremashvili V, Lokeshwar SD, Soloway MS, Pelaez L, Umar SA, Manoharan M, Jordá M.

Am J Surg Pathol. 2013 Feb;37(2):219-25. doi: 10.1097/PAS.0b013e318268ccc1.

PMID:
23095506
46.

A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens.

Hansel DE, Amin MB, Comperat E, Cote RJ, Knüchel R, Montironi R, Reuter VE, Soloway MS, Umar SA, Van der Kwast TH.

Eur Urol. 2013 Feb;63(2):321-32. doi: 10.1016/j.eururo.2012.10.008. Epub 2012 Oct 12. Review.

PMID:
23088996
47.

ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate.

Palou J, Wood D, Bochner BH, van der Poel H, Al-Ahmadie HA, Yossepowitch O, Soloway MS, Jenkins LC; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012.

Eur Urol. 2013 Jan;63(1):81-7. doi: 10.1016/j.eururo.2012.08.011. Epub 2012 Aug 14. Review.

PMID:
22938869
48.

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.

Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012.

Eur Urol. 2013 Jan;63(1):45-57. doi: 10.1016/j.eururo.2012.08.009. Epub 2012 Aug 14. Review.

PMID:
22917985
49.

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012.

Eur Urol. 2013 Jan;63(1):58-66. doi: 10.1016/j.eururo.2012.08.010. Epub 2012 Aug 14. Review.

PMID:
22917984
50.

ICUD-EAU International Consultation on Bladder Cancer 2012: Recommendations on bladder cancer-progress in a cancer that lacks the limelight.

Soloway MS.

Eur Urol. 2013 Jan;63(1):1-3. doi: 10.1016/j.eururo.2012.07.045. Epub 2012 Jul 31. No abstract available.

PMID:
22868670

Supplemental Content

Loading ...
Support Center